BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Welling TH, Fu S, Wan S, Zou W, Marrero JA. Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. Cancer Invest 2012;30:689-97. [PMID: 23072563 DOI: 10.3109/07357907.2012.732161] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Wan S, Kuo N, Kryczek I, Zou W, Welling TH. Myeloid cells in hepatocellular carcinoma. Hepatology 2015;62:1304-12. [PMID: 25914264 DOI: 10.1002/hep.27867] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 11.1] [Reference Citation Analysis]
2 Choi SH, Park JY, Kang W, Kim SU, Kim do Y, Ahn SH, Ro SW, Han KH. Knockdown of HIF-1α and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. Apoptosis 2016;21:85-95. [PMID: 26467924 DOI: 10.1007/s10495-015-1185-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yao X, Yin X, Lu W, Cao L, Tan S. Identifying a Six-Gene Signature Predicting Response to TACE in Hepatocellular Carcinoma by Bioinformatics Analysis. Journal of Nanomaterials 2021;2021:1-10. [DOI: 10.1155/2021/3249816] [Reference Citation Analysis]
4 Mußbach F, Ungefroren H, Günther B, Katenkamp K, Henklein P, Westermann M, Settmacher U, Lenk L, Sebens S, Müller JP, Böhmer FD, Kaufmann R. Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer 2016;15:54. [PMID: 27473374 DOI: 10.1186/s12943-016-0538-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
5 Mathew S, Ali A, Abdel-hafiz H, Fatima K, Suhail M, Archunan G, Begum N, Jahangir S, Ilyas M, Chaudhary AG, Al Qahtani M, Mohamad Bazarah S, Qadri I. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infection, Genetics and Evolution 2014;26:327-39. [DOI: 10.1016/j.meegid.2014.06.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA, Schaalan MF. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis? J Immunotoxicol. 2013;10:380-386. [PMID: 23350952 DOI: 10.3109/1547691x.2012.758198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
7 Huang W, Chen Z, Zhang L, Tian D, Wang D, Fan D, Wu K, Xia L. Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice. Gastroenterology 2015; 149: 1053-67. e14. [PMID: 26065367 DOI: 10.1053/j.gastro.2015.05.058] [Cited by in Crossref: 70] [Cited by in F6Publishing: 78] [Article Influence: 10.0] [Reference Citation Analysis]
8 Shakiba E, Sadeghi M, Shakiba M. A systematic review and meta-analysis of evaluation of serum interleukin 8 levels in hepatocellular carcinoma. Clin Exp Hepatol 2019;5:123-8. [PMID: 31508492 DOI: 10.5114/ceh.2019.84780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Pan X, Kaminga AC, Wen SW, Liu A. Chemokines in hepatocellular carcinoma: a meta-analysis. Carcinogenesis 2020;41:1682-94. [PMID: 33300549 DOI: 10.1093/carcin/bgaa106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hou YC, Wang CJ, Chao YJ, Chen HY, Wang HC, Tung HL, Lin JT, Shan YS. Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes. J Clin Med 2018;7:E502. [PMID: 30513776 DOI: 10.3390/jcm7120502] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
11 Li H, Zhang L. Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapy. Oncotarget 2017;8:1805-13. [PMID: 27655683 DOI: 10.18632/oncotarget.12101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
12 Cai H, Zhang Y, Meng F, Cui C, Li H, Sui M, Zhang H, Lu S. Preoperative Serum IL6, IL8, and TNF-α May Predict the Recurrence of Hepatocellular Cancer. Gastroenterol Res Pract 2019;2019:6160783. [PMID: 31781194 DOI: 10.1155/2019/6160783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Li L, Chan SL, Mo F, Hui EP, Koh J, Chan AKC, Tang NLS, Lee KF, Lai PBS, Yu SCH, Yeo W. Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma. Cancer Manag Res 2019;11:2719-27. [PMID: 31040713 DOI: 10.2147/CMAR.S178482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Cao Z, Xiao H, Li L, Liu M, Lin G, Zhai P, Yong KT, Wang X, Xu G. The Codelivery of siRNA and QDs by pH-Responsive Micelle for Hepatoma Cancer Cells. Front Pharmacol 2019;10:1194. [PMID: 31680969 DOI: 10.3389/fphar.2019.01194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Chiu YS, Hsing CH, Li CF, Lee CY, Hsu YH, Chang MS. Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma. Sci Rep 2017;7:17609. [PMID: 29242565 DOI: 10.1038/s41598-017-17054-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
16 Ye BG, Sun HC, Zhu XD, Chai ZT, Zhang YY, Ao JY, Cai H, Ma DN, Wang CH, Qin CD, Gao DM, Tang ZY. Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma. Oncotarget 2016;7:29333-45. [PMID: 27121053 DOI: 10.18632/oncotarget.8787] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
17 Nischalke HD, Fischer J, Klüners A, Matz-Soja M, Krämer B, Langhans B, Goeser F, Soyka M, Stickel F, Spengler U, Nattermann J, Strassburg CP, Berg T, Lutz P. A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. Liver Int 2021;41:2139-48. [PMID: 34051061 DOI: 10.1111/liv.14980] [Reference Citation Analysis]